Enns D, Karmazyn M, Mair J, Lercher A, Kountchev J, Belcastro A
School of Kinesiology, Faculty of Health Sciences, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Mol Cell Biochem. 2002 Dec;241(1-2):29-35. doi: 10.1023/a:1020861120368.
The purpose of this study was to test the hypothesis that myocardial ischemia-reperfusion (I/R) is accompanied by an early burst in calpain activity, resulting in decreased calpastatin activity and an increased calpain/calpastatin ratio, thereby promoting increased protein release. To determine the possibility of a 'calpain burst' impacting cardiac calpastatin inhibitory activity, rat hearts were subjected (Langendorff) to either 45 or 60 min of ischemia followed by 30 min of reperfusion with and without pre-administration (s.c.) of a cysteine protease inhibitor (E-64c). Myocardial function, calpain activities (casein release assay), calpastatin inhibitory activity and release of CK, LDH, cTnI and cTnT were determined (n = 8 for all groups). No detectable changes in calpain activities were observed following I/R with and without E-64c (p > 0.05). Both I/R conditions reduced calpastatin activity (p < 0.05) while E-64c pre-treatment was without effect, implicating a non-proteolytic event underlying the calpastatin changes. A similar result was noted for calpain-calpastatin ratios and the release of all marker proteins (p < 0.05). In regard to cardiac function, E-64c resulted in transient improvements (15 min) for left ventricular developed pressure (LVDP) and rate of pressure development (p < 0.05). E-64c had no effect on end diastolic pressure (LVEDP) or coronary pressure (CP) during I/R. These findings demonstrate that restricting the putative early burst in calpain activity, suggested for I/R, by pre-treatment of rats with E-64c does not prevent downregulation of calpastatin inhibitory activity and/or protein release despite a transient improvement in cardiac function. It is concluded that increases in calpain isoform activities are not a primary feature of l/R changes, although the role of calpastatin downregulation remains to be elucidated.
心肌缺血再灌注(I/R)伴随着钙蛋白酶活性的早期爆发,导致钙蛋白酶抑制蛋白活性降低以及钙蛋白酶/钙蛋白酶抑制蛋白比率升高,从而促进蛋白质释放增加。为了确定“钙蛋白酶爆发”影响心脏钙蛋白酶抑制蛋白抑制活性的可能性,对大鼠心脏(采用Langendorff灌流法)进行45或60分钟的缺血处理,随后在有或没有预先皮下注射半胱氨酸蛋白酶抑制剂(E-64c)的情况下进行30分钟的再灌注。测定心肌功能、钙蛋白酶活性(酪蛋白释放试验)、钙蛋白酶抑制蛋白抑制活性以及肌酸激酶(CK)、乳酸脱氢酶(LDH)、心肌肌钙蛋白I(cTnI)和心肌肌钙蛋白T(cTnT)的释放情况(所有组n = 8)。在有或没有E-64c的I/R处理后,未观察到钙蛋白酶活性有可检测到的变化(p>0.05)。两种I/R情况均降低了钙蛋白酶抑制蛋白活性(p<0.05),而E-64c预处理无效,这表明钙蛋白酶抑制蛋白变化背后存在非蛋白水解事件。钙蛋白酶-钙蛋白酶抑制蛋白比率以及所有标记蛋白的释放也得到了类似结果(p<0.05)。关于心脏功能,E-64c使左心室舒张末压(LVDP)和压力上升速率在15分钟内出现短暂改善(p<0.05)。E-64c在I/R期间对舒张末期压力(LVEDP)或冠状动脉压力(CP)没有影响。这些发现表明,尽管对心脏功能有短暂改善,但用E-64c预处理大鼠以限制I/R中假定的钙蛋白酶活性早期爆发,并不能防止钙蛋白酶抑制蛋白抑制活性下调和/或蛋白质释放。得出的结论是,钙蛋白酶同工型活性增加不是I/R变化的主要特征,尽管钙蛋白酶抑制蛋白下调的作用仍有待阐明。